SCHEMBL12439730

SCHEMBL12439730

Clc1nc(-c2cncc(Br)c2)no1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 1/20 0.45
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
HTT P42858 1/20 0.40
CYP11B2 P19099 1/20 0.39
CYP2A6 P11509 2/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNA5 P30532 1/20 0.39
CHRNA4 P43681 1/20 0.39
S1PR1 P21453 3/20 0.37
TP53 P04637 2/20 0.37
SIRT2 Q8IXJ6 1/20 0.36
S1PR3 Q99500 2/20 0.36
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
GAA P10253 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4207138 0.81 L3MBTL1 (0.51) PTK2NPC1RAB9ASMN1; SMN2CYP11B2
SCHEMBL19791497 0.79 S1PR1 (0.52) NPC1RAB9ASMN1; SMN2CYP2A6S1PR1
SCHEMBL1422895 0.76 CHRNB2 (0.73) NPC1RAB9ASMN1; SMN2CHRNB2CHRNA5
SCHEMBL2156909 0.76 NPC1 (0.46) PTK2NPC1RAB9ASMN1; SMN2CYP11B2
SCHEMBL10498616 0.76 PTK2 (0.49) PTK2RAB9AHTTCYP11B2CYP2A6
SCHEMBL25231377 0.74 HPGDS (0.41) PTK2NPC1RAB9ACYP11B2S1PR1
SCHEMBL4197856 0.71 GRM5 (0.61) NPC1RAB9ASMN1; SMN2S1PR1TP53
SCHEMBL4211392 0.71 ACHE (0.47) PTK2NPC1RAB9ASMN1; SMN2CYP11B2
SCHEMBL2433394 0.71 NOTUM (0.41) PTK2NPC1RAB9ASMN1; SMN2HTT
SCHEMBL14392676 0.71 CYP2A6 (0.61) PTK2RAB9AHTTCYP11B2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8912216-B2 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2014-12-16 US disclosed
US-8912216-B2 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2014-12-16 US disclosed
US-20140038960-A1 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2014-02-06 US disclosed
US-20140038960-A1 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2014-02-06 US disclosed
US-20120295902-A1 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2012-11-22 US disclosed
US-20120295902-A1 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2012-11-22 US disclosed
WO-2011095196-A1 HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140038960-A1 Hetaryl-[1,8]naphthyridine derivatives ATP5F1A, ATP5ME, ATP5F1D PTK2 3895/4885NPC1 261/4885RAB9A 860/4885
US-20120295902-A1 Hetaryl-[1,8]naphthyridine derivatives ATP5F1A, ATP5ME, ATP5F1D PTK2 3895/4885NPC1 261/4885RAB9A 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.